Navigation Links
Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference
Date:12/11/2007

QualityBLUE program works with hospitals to help reduce spread of MRSA

PITTSBURGH, Dec. 11 /PRNewswire/ -- At a national forum on quality in health care, Highmark officials presented information on one aspect of their pay-for-performance program designed to deal with Methicillin Resistant Staphylococcus Aureus (MRSA). Highmark's program, called QualityBLUE, has been extremely successful for hospitals in western Pennsylvania in identifying patients that have been infected with the disease.

"By identifying patients who are carriers of MRSA earlier than in the past, hospitals are reducing the spread of the disease and reducing mortality, decreasing length of stay and use of antibiotics, and ultimately having significantly improved outcomes for patients," said Deborah Donovan, director, Provider Quality Performance Management at Highmark. "Highmark is working collaboratively with 30 hospitals in Pennsylvania. It is in great part because of this cooperation that the program has been so successful."

The poster presentation was made today at the 19th Annual National Forum on Quality Improvement for Health Care in Orlando, Fla. and sponsored by the Institute for Healthcare Improvement (IHI). In December 2006, the IHI added the reduction of MRSA infections to its new 5 Million Lives campaign. Participating hospitals submit such data as the percentage of patients who were tested for MRSA on admission and compliance with prevention techniques.

Highmark's pay-for-performance program began targeting MRSA testing and prevention initiatives in July 2005. "We have made it easier for participating hospitals to work with IHI and Highmark," said Donovan.

Results from Highmark's fiscal year 2007 review show that during the past year, 8.4 percent of patients admitted to hospitals' high-risk areas such as the intensive care unit were identified as carriers of MRSA. With the thorough screening program, the spread of MRSA has been reduced. Measures that participating hospitals use to reduce the spread once the patient is identified as a carrier include placing the patient in isolation, using dedicated equipment, and strict adherence to appropriate hand hygiene.

Donovan says the QualityBLUE program has expanded for fiscal year 2008 for the participating hospitals in western and central Pennsylvania. Each hospital identified three units within its facility for intense activities designed to reduce MRSA transmission.

Highmark Inc.

As one of the leading health insurers in Pennsylvania, Highmark Inc.'s mission is to provide access to affordable, quality health care enabling individuals to live longer, healthier lives. Based in Pittsburgh, Highmark serves 4.6 million people through the company's health care benefits business. Highmark contributes millions of dollars to help keep quality health care programs affordable and to support community-based programs that work to improve people's health. Highmark exerts an enormous economic impact throughout Pennsylvania. A recent study states that Highmark's positive impact exceeded $2.5 billion. The company provides the resources to give its members a greater hand in their health.

Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. For more information, visit http://www.highmark.com.


'/>"/>
SOURCE Highmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that ... a decade after surgery, though activity levels decline over time. The study, presented ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute ... marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy ... of reoccurrence and relapse. With such a challenging diagnosis that requires immediate ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of ... up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week ... Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every ...
(Date:7/20/2017)... ... ... The Dermatology Clinic announced today the addition of Dr. Scott W. Dunbar, ... graduating summa cum laude. He attended Emory University School of Medicine in Atlanta where ... Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship to become ...
(Date:7/20/2017)... Alexandria, VA (PRWEB) , ... July 20, 2017 , ... ... annual Social Security cost – of - living - adjustment (COLA) is a bad ... The proposed “chained” consumer price index (CPI) would grow even more slowly than ...
Breaking Medicine News(10 mins):